Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ras protein activator like 1 (RASAL1) is a member of the GAP1 family of GTPase-activating proteins that suppress RAS function by enhancing the intrinsic GTPase activity of RAS proteins, thus converting active RAS-GTP to the inactive RAS-GDP form. This crucial regulation prevents excessive cell proliferation and maintains normal cellular signaling. RASAL1 is highly expressed in endocrine tissues and is implicated in the negative regulation of the Ras-ERK/MAPK pathway. Loss or dysfunction of RASAL1 has been associated with increased Ras pathway activity and contributes to the development of various cancers and proliferative disorders.
For theoretical inhibitors: Inhibition or modulation of RASAL1 would affect Ras deactivation and downstream MAPK/ERK signaling. RASAL1 itself inactivates RAS by accelerating GTP hydrolysis, converting active RAS-GTP to inactive RAS-GDP.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ras protein activator like 1 (RASAL1).